{"product_id":"arqt-five-forces","title":"(ARQT) Arcutis Biotherapeutics, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Arcutis Biotherapeutics, Inc. Porter's Five Forces Analysis explains the competitive pressures affecting the company, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real sample of the analysis, and the full purchase gives you the complete ready-to-use version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics depends on specialized active pharmaceutical ingredients and formulation inputs for its topical dermatology products, and these must meet strict quality and regulatory standards. That narrows the supplier base, so qualified vendors can push on price, delivery timing, and contract terms. With about $138 million in 2024 net product sales, supply continuity matters because any input delay can hit launches and margins fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO and manufacturing reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. depends on CDMOs for clinical and commercial supply of ZORYVE, so suppliers hold more power when capacity is tight. Switching a manufacturing partner can take months because of tech transfer, validation, and CMC filing updates, which makes fast scale-up harder. That matters more after ZORYVE's 2024 rosacea approval and 2025 plaque psoriasis expansion, when demand can rise faster than supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality and compliance constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers that can meet cGMP, stability, and contamination-control rules are scarce, so Arcutis Biotherapeutics, Inc. has less room to push pricing or terms. For topical drugs, only a small pool of vendors can handle specific formulation and packaging needs, which raises supplier power. If a quality failure triggers a batch reject or delay, Arcutis can face costly supply gaps and become even more dependent on the few reliable suppliers left.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePackaging and delivery components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. faces moderate supplier power in packaging and delivery components because its creams, foams, and other topical products need specialized containers, applicators, and barrier packs that protect stability and support patient use. With few compliant suppliers for these systems, switching costs rise and pricing pressure can build.\u003c\/p\u003e\n\u003cp\u003eThis matters most for a small commercial base: even one packaging bottleneck can delay launches, raise unit costs, and reduce flexibility in sourcing. Supplier leverage is strongest when materials must meet FDA-quality standards and child-resistant or precision-dosing needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized packs limit sourcing options.\u003c\/li\u003e\n\u003cli\u003eCompliance raises supplier switching costs.\u003c\/li\u003e\n\u003cli\u003eLow-volume orders weaken bargaining power.\u003c\/li\u003e\n\u003cli\u003ePackaging delays can hit sales timing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate but manageable supplier leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. has moderate supplier leverage because it is still far smaller than big pharma buyers, so key API, fill-finish, and packaging vendors can press on price and terms. In 2024, Arcutis reported $181.8 million in net product revenue, but it still lacks the scale of large drugmakers, so supplier power stays real but not extreme.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplier power: moderate\u003c\/li\u003e\n\u003cli\u003eScale limits buyer leverage\u003c\/li\u003e\n\u003cli\u003eMulti-source plans can reduce risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eArcutis can soften this by qualifying backup vendors and spreading critical inputs across more than one source. That makes the risk manageable, especially for specialized biologic and dermatology supply chains where switching costs can be high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Faces Moderate Supplier Risk Behind $181.8M in Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. faces moderate supplier power because ZORYVE depends on specialized APIs, CDMOs, and compliant packaging that are hard to replace fast. In 2024, net product revenue was $181.8 million, so any supply delay can hit sales and margins. Tech transfer, validation, and FDA filing updates keep switching costs high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net product revenue\u003c\/td\u003e\n\u003ctd\u003e$181.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier power\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey risk\u003c\/td\u003e\n\u003ctd\u003eCDMO\/API bottlenecks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Arcutis Biotherapeutics, Inc.’s competitive pressures, supplier and buyer power, entry threats, and substitutes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick Porter's Five Forces snapshot for Arcutis Biotherapeutics—clarifies competitive pressure and strategic risk in seconds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Arcutis Biotherapeutics, Inc., helping validate claims, reduce uncertainty, and support faster, more defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh payer influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurers and pharmacy benefit managers control most dermatology access in the U.S., where PBMs manage about 80% of prescriptions. \u003c\/p\u003e\n\u003cp\u003eEven when physicians prescribe Arcutis Biotherapeutics, Inc. products, prior authorization and formulary placement can slow or block fills, so uptake depends on payer rules, not just clinical demand. \u003c\/p\u003e\n\u003cp\u003eThis gives system-level buyers strong bargaining power and can pressure net pricing and volume. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescriber choice matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescriber choice is a real constraint for Arcutis Biotherapeutics, Inc. Dermatologists can pick from dozens of branded and generic topical options, so if ZORYVE does not show a clear edge in efficacy or ease of use, adoption can lag. That makes switching easy and keeps pressure on price, with Arcutis relying on one commercial brand family to win share through differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient sensitivity to cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. faces high customer price sensitivity because its topical therapies are used long term for chronic skin disease. If copays rise or coverage is thin, patients can stop therapy fast, so access programs matter and pricing power stays limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFormulary access is crucial\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePreferred formulary access can move Arcutis Biotherapeutics, Inc. from niche use to broad prescribing, so it directly lifts ZORYVE volume. Payers can trade access for rebates, prior auth, and step edits, which strengthens customer power and trims net price per fill.\u003c\/p\u003e\n\u003cp\u003eFor a dermatology brand, access is often the sales gate. If coverage is narrow, even strong demand stalls at the pharmacy counter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreferred coverage drives more scripts.\u003c\/li\u003e\n\u003cli\u003eRebates cut realized pricing.\u003c\/li\u003e\n\u003cli\u003ePrior auth slows conversion.\u003c\/li\u003e\n\u003cli\u003eStep edits raise payer leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate to high customer power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. sells into a market shaped by payers, clinicians, and patients, so buying power stays moderate to high. Health plans can steer use through prior auth and formulary access, while doctors still choose based on efficacy, tolerability, and ease of use.\u003c\/p\u003e\n\u003cp\u003eThat leaves Arcutis Biotherapeutics, Inc. some room to compete on convenience and skin-friendly profiles, but buyer discipline is still strong. If coverage is weak or copays rise, demand can shift fast to lower-cost or better-covered therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple buyer groups shape demand\u003c\/li\u003e\n\u003cli\u003eCoverage controls can limit uptake\u003c\/li\u003e\n\u003cli\u003eDifferentiation helps, but only partly\u003c\/li\u003e\n\u003cli\u003eOverall customer power: moderate to high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBM Control Keeps Arcutis’ Pricing Power in Check\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power is high for Arcutis Biotherapeutics, Inc. because PBMs manage about 80% of U.S. prescriptions and can shape access through prior auth, step edits, and formulary tiers.\u003c\/p\u003e\n\u003cp\u003eDermatologists also have many topical alternatives, so switching costs are low and pricing power stays limited.\u003c\/p\u003e\n\u003cp\u003eFor chronic skin disease, copays and coverage gaps can cut fills fast, so payer and patient discipline both pressure volume and net price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM control\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlternatives\u003c\/td\u003e\n\u003ctd\u003eMany\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient sensitivity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall power\u003c\/td\u003e\n\u003ctd\u003eModerate to high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eArcutis Biotherapeutics, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Arcutis Biotherapeutics, Inc. Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. It is the same professionally written document, fully formatted and ready to use. Once you complete your purchase, you’ll get instant access to this exact file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDense dermatology competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. faces dense dermatology rivalry because psoriasis, atopic dermatitis, seborrheic dermatitis, vitiligo, eczema, and alopecia each have multiple branded options from large pharma and specialty biopharma. The fight is for prescriber attention and formulary access, not just patients. Arcutis reported $164.5 million in 2024 net product revenue, so share gains still depend on beating better-funded rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded and generic pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany dermatology lines are crowded with entrenched brands and low-cost generics, and in the U.S. generics make up about 90% of prescriptions but only around 18% of drug spend. That makes it harder for Arcutis Biotherapeutics, Inc. to win share against standard-of-care products that doctors already know. Price cuts from generics also raise rivalry for newer brands, because payers push down net prices and make switching less sticky.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline races\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcutis is in a fast pipeline race: ZORYVE roflumilast already has 4 FDA approvals, and JAK1 programs target more overlapping inflammatory skin diseases. Rivals are pushing new topical and systemic options in the same spaces, so the winner often comes down to who gets approved first and who wins a broader label. In a market where ZORYVE sales rose to 2024 levels above $200 million, even a few months' lead can shift early share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePromotion and evidence matter\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is intense because Arcutis Biotherapeutics, Inc. competes on proof, not hype. In chronic dermatology, prescribers compare tolerability, efficacy, and ease of use, so clinical differentiation and real-world evidence can decide share. That pushes rivals to spend more on trials and promotion, raising sales and R\u0026amp;D pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic use raises switching costs\u003c\/li\u003e\n\u003cli\u003eEvidence shapes prescriber trust\u003c\/li\u003e\n\u003cli\u003eBetter convenience can win scripts\u003c\/li\u003e\n\u003cli\u003ePromotion and trials lift rivalry costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh rivalry overall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. competes in a crowded dermatology market against larger, well-funded peers, so rivalry is high. Its R\u0026amp;D spend was $202.5 million in 2024, while net product revenue was $190.2 million, showing how hard it is to turn clinical wins into durable share. Success depends on proving clear benefit versus current standards on efficacy, safety, and convenience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany strong rivals compete\u003c\/li\u003e\n\u003cli\u003eProof of benefit drives adoption\u003c\/li\u003e\n\u003cli\u003eRivalry remains high overall\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Faces Intense Competition as ZORYVE Grows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Arcutis Biotherapeutics, Inc. because ZORYVE competes in crowded chronic skin markets with many branded and generic options, and payers press hard on price. Arcutis Biotherapeutics, Inc. reported $190.2 million 2024 net product revenue and $202.5 million 2024 R\u0026amp;D spend, so growth still depends on winning share with clear clinical and convenience benefits. Fast label expansion helps, but it also keeps rivals close.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$190.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$202.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZORYVE FDA approvals\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther prescription therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients can switch to other prescription creams, foams, biologics, or oral agents, so Arcutis Biotherapeutics, Inc. faces a real substitution risk. In plaque psoriasis and atopic dermatitis, physicians already have many approved options, and if Arcutis does not beat rivals on convenience or skin-clearance results, they can move fast. That keeps pricing power limited and makes the threat of substitutes significant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and systemic drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiologics and systemic drugs remain real substitutes for Arcutis Biotherapeutics, Inc. in moderate-to-severe inflammatory skin disease, where many payers and doctors favor them despite higher cost. Dupilumab alone generated roughly $14 billion in 2025 sales, showing how strong that option is. That scale limits Arcutis Biotherapeutics, Inc.’s pricing power for topical therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTC and supportive care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTC creams, moisturizers, medicated shampoos, and other nonprescription care can handle mild symptoms, so they cap Arcutis Biotherapeutics, Inc.’s pricing power in less severe cases. Prescription dermatology still wins on efficacy, but cheaper OTC options can delay or replace treatment when disease is mild. That pressure is real in a large market: psoriasis affects about 7.5 million U.S. adults, and many begin with self-care before escalating to Rx therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOff-label and step-therapy substitutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers can force step therapy, so patients may need to fail older, cheaper drugs before Arcutis Biotherapeutics, Inc. products are covered. Off-label use of familiar topicals and steroids is also a real substitute, which can slow uptake even when Arcutis Biotherapeutics, Inc. shows better tolerability or efficacy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eStep edits delay branded access.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eOff-label drugs stay cheap and familiar.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAdoption can lag clinical demand.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate to high substitution threat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDermatology has many substitute paths, from generic topicals to biologics and oral therapies, so switching away from Arcutis Biotherapeutics, Inc. is still fairly easy. That keeps the threat of substitutes moderate to high, especially when payers push for lower cost options.\u003c\/p\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. must keep showing better efficacy, safety, or convenience to protect share, because even a small drop in differentiation can move patients to other branded or generic treatments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany treatment options weaken stickiness.\u003c\/li\u003e\n\u003cli\u003ePrice pressure from payers stays high.\u003c\/li\u003e\n\u003cli\u003eDifferentiation must stay clear.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitute Threat Pressures Arcutis Pricing Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Arcutis Biotherapeutics, Inc. is high: branded biologics, oral drugs, OTC creams, and off-label steroids all compete for the same dermatology patients. Dupilumab reached about $14 billion in 2025 sales, showing how strong the biologic alternative is. Step edits and cheap generics keep pricing power under pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupilumab\u003c\/td\u003e\n\u003ctd\u003e~$14B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC\/generics\u003c\/td\u003e\n\u003ctd\u003eLow-cost first line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory barriers make Arcutis Biotherapeutics, Inc.'s market hard to enter: a new drug usually needs 10–15 years of testing and FDA review, and the average cost can top $2 billion. Even after approval, firms face post-market safety checks and compliance costs, so rivals need deep cash and patience. For a dermatology biotech like Arcutis Biotherapeutics, Inc., that delay and capital burn keep the threat of new entrants low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R and D costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh R and D costs raise Arcutis Biotherapeutics, Inc. entry barriers because a dermatology pipeline needs heavy spend on discovery, formulation, Phase 1 to 3 trials, and launch support. Late-stage dermatology trials often cost tens of millions of dollars per asset, and development can run 7 to 10 years, so most newcomers cannot fund several programs at once. That makes fast, broad entry unlikely and keeps new competition low.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand and trust requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescribers and payers favor brands with strong clinical data and steady supply, and Arcutis Biotherapeutics, Inc. has built that moat around ZORYVE, now approved in 3 dermatology indications. New entrants must match that evidence base and win trust against entrenched brands, so launch costs stay high and adoption stays slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcutis Biotherapeutics, Inc. and its rivals depend on patents and trade secrets to protect formulations and approved uses, so a strong IP wall can slow direct copycat entry. But patent coverage does not stop indirect rivals, and new entrants can still compete with new mechanisms or better delivery systems.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents delay generic-style copying.\u003c\/li\u003e\n\u003cli\u003eIP lowers near-term entry risk.\u003c\/li\u003e\n\u003cli\u003eNovel platforms can still bypass patents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate threat overall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThreat of new entrants is moderate: FDA dermatology drug development usually needs years of trials, heavy CMC work, and high capital, but biotech still keeps producing challengers. Big pharma can also move fast by buying or licensing assets, so the barrier is high, not closed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh R\u0026amp;D and regulatory costs\u003c\/li\u003e\n\u003cli\u003eBiotech still creates new rivals\u003c\/li\u003e\n\u003cli\u003eLarge pharma can acquire assets\u003c\/li\u003e\n\u003cli\u003eOverall threat: moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcutis Faces Moderate Entry Threat, Backed by ZORYVE’s Moat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Arcutis Biotherapeutics, Inc. is moderate. FDA skin-drug entry still means roughly 10–15 years, often $1B+ in R and D, plus costly Phase 1 to 3 trials and CMC work. Arcutis Biotherapeutics, Inc.'s ZORYVE moat, now in 3 indications, raises launch and trust barriers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime\u003c\/td\u003e\n\u003ctd\u003e10–15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost\u003c\/td\u003e\n\u003ctd\u003e$1B+ R and D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMoat\u003c\/td\u003e\n\u003ctd\u003e3 ZORYVE indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233963221257,"sku":"arqt-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/arqt-five-forces.webp?v=1785711459","url":"https:\/\/dcfanalyst.com\/products\/arqt-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}